Fueled by a sustained boom in sales of its diabetes and obesity products, Eli Lilly will become the world’s top-seller of prescription drugs by 2030 and will hold the top rung by a wide margin. | ...

Review the current Eli Lilly and Co (LLY:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if LLY is the best investment for you.

Eli Lilly is looking to approach regulators for approval of its once-weekly insulin for type 2 diabetes (T2D) after it proved non-inferior to daily dosing. The QWINT-1 (NCT05662332), QWINT-3 ...

Global shares were mostly higher Wednesday and oil prices slipped as investors awaited a decision on interest rates by the ...

Eli Lilly also stated it would appeal, commenting that it “remains confident in the clinical efficacy and cost-effectiveness of donanemab.” Professor Fiona Carragher, Alzheimer’s Society’s chief ...